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Abstract. Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that recently re-emerged in Africa and
rapidly spread into countries of the Indian Ocean basin and South-East Asia. The mean viremic blood donation risk for
CHIKV on La Re´union reached 1.5% at the height of the 2005–2006 outbreaks, highlighting the need for development
of safety measures to prevent transfusion-transmitted infections. We describe successful inactivation of CHIKV in human
platelets and plasma using photochemical treatment with amotosalen and long wavelength UVA illumination. Platelet
components in additive solution and plasma units were inoculated with two different strains of high titer CHIKV stock
(6.0–8.0 logs/mL), and then treated with amotosalen and exposure to 1.0–3.0 J/cm2 UVA. Based on in vitro assays
of infectious virus pre- and post-treatment to identify endpoint dilutions where virus was not detectable, mean viral titers
could effectively be reduced by > 6.4 ± 0.6 log10 TCID50/mL in platelets and ³ 7.6 ± 1.4 logs in plasma, indicating this
treatment has the capacity to prevent CHIKV transmission in human blood components collected from infected donors
in or traveling from areas of CHIKV transmission.
INTRODUCTION
Emergence/re-emergence of arthropod-borne viruses (arbo-
viruses) in new geographic ranges poses a considerable chal-
lenge for transfusion medicine worldwide. Highlighted by
the West Nile virus (WNV) epidemics in North America,
dengue virus (DENV) epidemics in Puerto Rico, Brazil, and
Honduras, and the establishment of DENV transmissions
in Florida, arboviruses are now considered as “significant
transfusion-transmissible pathogens.”1 The 2012 WNV data
for the United States include over 240 presumptive viremic
blood donors—already exceeding the total of 137 for 20112;
although both WNV and DENV are members of the
Flaviviridae, chikungunya virus (CHIKV) is in the Alphavirus
genus of the family Togaviridae. Beginning in 2004, an epi-
demic of CHIKV emerged in coastal areas of East Africa3,4
and rapidly spread into countries of the Indian Ocean basin,5–9
South-East Asia,10–13 India,14 China,15 and Europe.16–18 The
total number of CHIKV infections remains undetermined,
although in India alone it has been estimated that it has recently
caused between 2 and 6.5 million cases of arthritic disease.19
In addition, fatalities were repeatedly documented in associa-
tion with CHIKV infection, although involvement of underlying
medical conditions or coinfections with other pathogens in fatal
cases could not be disregarded.20–25 There are no antivirals or
licensed vaccines available to control CHIKV outbreaks.
Enzootic in tropical regions of Africa, CHIKV relies on trans-
mission between non-human primates and sylvatic, prima-
tophilic mosquitoes (Aedes furcifer-taylori, Aedes africanus,
Aedes luteocephalus, and Aedes neoafricanus).26,27 Occasional
spillovers result in CHIKV introduction into rural areas caus-
ing outbreaks transmitted by highly anthropophilic Aedes
aegypti and Aedes albopictus mosquitoes. The CHIKV is
also endemic in South-East Asia where it is maintained in a
strictly urban cycle involving Ae. aegypti and most recently,
Ae. albopictus.26 The genetic adaptation of CHIKV to trans-
mission by Ae. albopictus was postulated as one of the major
factors that contributed to the magnitude and geographic dis-
persal of the recent CHIKV epidemics.28,29 Aedes albopictus
is now present on all continents except Antarctica and con-
tinues to expand its range,30 posing the threat of introduction
and possible establishment of CHIKV in new geographic areas
including the Americas. The CHIKV outbreaks in Northern
Italy in 2007 and France in 201016–18 underscore the plausibility
of future expansion of CHIKV.
Although CHIKV infection by transfusion of donated blood
products has not been documented, the explosive global
CHIKV expansion in recent years warrants a considerable revi-
sion of blood management systems in affected regions.1 Thus,
during the Italian CHIKV outbreak of 2007 and the 2005–2006
epidemic in the French island La Re´union, all blood collections
were suspended,31–33 and the required blood was delivered
from unaffected regions of Italy or continental France. How-
ever, the 5-day shelf life of platelet components precluded their
being delivered to La Re´union from France and pathogen inac-
tivation was instituted on an emergency basis to provide safe
platelets for patients there.32 The relatively short duration of
the viremic period (6–7 days) and low rates of asymptomatic
infections (3% to 25%)34–36 have been proposed as factors that
decrease the risk of contamination of donated blood with
CHIKV.1 However, the extremely high attack rates observed
during CHIKV epidemics (34–75%) probably equalize these
factors, resulting in an overall increase in the transfusion risk
of CHIKV.3,5,37 Using mathematical models, it was estimated
that during the 2005–2006 outbreak in La Re´union, the mean
viremic blood donation risk was 0.132% and reached 1.5%
at the height of the outbreak.33 Analysis of donated platelets
for the presence of CHIKV RNA in Italy revealed a 0.4%
contamination rate, which is in agreement with the mathemat-
ical model prediction (0.7%).31
The photochemical treatment of therapeutic units of human
platelet and plasma components using amotosalen, a synthetic
psoralen, and UVA (320–400 nm; INTERCEPT Blood System
[IBS]; Cerus Corporation, Concord, CA) is a highly efficient
method for inactivation of a broad variety of blood borne patho-
gens, including bacteria, viruses, protozoa, and leukocytes.38–46
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The inactivation technology is based on the ability of
psoralens to intercalate into double-stranded forms of RNA
or DNA, or hairpins of single-stranded RNA or DNA. Treat-
ment of the resultant complexes with UVA illumination leads
to the formation of inter- and cross-strand links between
pyrimidine bases, which prevents pathogen replication and
transcription.47 In vitro studies have shown that photochemical
treatment with amotosalen and UVA does not substantially
affect platelet or plasma function40,41,48,49 and clinical trials
indicated that transfusion of psoralen-treated platelets or
plasma to patients does not result in adverse immunologic or
hemorrhagic responses.50–53 More than a million kits to prepare
IBS platelets and plasma have been sold since the introduction of
the system inEurope.Detailed haemovigilance and postmarket-
ing surveillance in Europe since 2003 continues to demonstrate
safety and efficacy of the treated products.54–58
Although high levels of inactivation have been demonstrated
for a number of viruses including single-stranded RNA
viruses,38,40 the efficacy of amotosalen and UVA treatment
of inactivation of high CHIKV doses had not been tested.
Here, we describe the successful inactivation of high doses
of CHIKV in apheresis platelet concentrates and plasma com-
ponents using the amotosalen and UVA treatment process.
MATERIALS ANDMETHODS
CHIKV strain LR2006 OPY1 (GenBank accession no.:
DQ443544.2), was obtained from the World Reference Cen-
ter for Emerging Viruses and Arboviruses (WRCEVA) at the
University of Texas Medical Branch, Galveston, TX. The
strain was originally isolated in 2006 from a febrile patient
who returned to France from La Re´union. The strain was
passed five times on Vero cell culture and once in suckling
mice. The stock virus was prepared by infecting confluent
monolayers of Vero76 cells (obtained from ATCC, Rockville,
MD) in 150 cm2 flasks. Virus was propagated in Vero cells
at 37°C in Liebovitz’s L-15 medium (1X L-15, 10% fetal
bovine serum, 10% tryptose phosphate broth, 100 U/mL pen-
icillin, and 100 mg/mL streptomycin, 2 mM L-Glutamine),
harvested at 3 days post infection, aliquoted, and stored
at −80°C. The CHIKV strain S27 was obtained from the
ATCC and was propagated in Vero76 cells as described pre-
viously, using Earle’s Minimal Essential Medium (EE) in
place of L-15. This strain was originally isolated from patient
serum in Tanganyika, East Africa in 1953. The use of two
different strains isolated decades apart shows that viruses
containing different mutations accumulated over time are
equally sensitive to the inactivation protocol presented here.
Apheresis platelet concentrates, collected with the Amicus
cell separator (Fenwal Inc., Lake Zurich, IL) from randomly
selected routine donors, were suspended in ~110 mL autolo-
gous plasma and 180 mL of InterSol platelet additive solution
(NaAcetate·3H2O, 4.42 g/L; Na3Citrate·2 H2O, 3.18 g/L;
NaH2PO4·2H2O, 1.05 g/L; Na2HPO4, 3.05 g/L; NaCl, 4.52 g/L,
Fenwal Inc.). Each platelet concentrate was collected in acid
citrate dextrose anticoagulant according to AABB (formerly
the “American Association of Blood Banks”) standards to con-
tain ~2.8 + 1011 to 4.2 + 1011 platelets per unit. Platelets were
supplied byTheMemorial BloodCenter (St. Paul,MN). Plasma
components were collected in sodium citrate anticoagulant on
theHaemonetics PCS (HaemoneticsCorp.,Braintree,MA) and
were obtained as fresh-frozen plasma from Plasma Biological
Services (Memphis, TN).
Four replicate experiments were performed in platelet and
plasma components. For each replicate two ABO-matched
platelet units or two thawed, fresh-frozen plasma units were
pooled. The volume of each platelet pool was adjusted
to ~610 mL, as determined by weight (density is 1.01 g/mL),
with 37% autologous plasma/63% InterSol. The volume
of each plasma pool was adjusted to ~1,200 mL (density
1.023 g/mL). Approximately 30 mL was removed from each
pool and set aside. An aliquot of a previously prepared frozen
stock of CHIKV was quickly thawed in a 37°C water bath
and 0.5 mL was collected for titer determination. Six mL
of CHIKV stock was added to the platelet pool by a Luer
lock and 13 mL was added to the plasma pool, resulting in a
titer of ~106 and 108 50% tissue culture infectious doses
(TCID50)/mL, respectively. The previously withdrawn 30 mL
of blood component was then returned to the appropriate
container through the same Luer lock, rinsing any residual
virus through the docking tube and into the container. After
mixing, each pool was split into two units, generating a unit
1 and unit 2 for each experimental replicate. Each platelet unit
was ~285 mL and each plasma unit ~585 mL.
Each platelet and plasma unit was sterilely connected to the
appropriate INTERCEPT processing set (Cerus Corpora-
tion) and the contents were passed through a PL 2411 plastic
container holding 15 mL of 3 mM (platelets) or 6 mM
(plasma) amotosalen, and into a PL 2410 plastic illumination
container, resulting in a final amotosalen concentration
of ~150 mM. Samples were collected to determine the initial
virus titer.
Each unit 1 received a single 3.0 J/cm2 UVA treatment, and
each unit 2 received two consecutive 1.03 J/cm2 treatments.
These doses are equal to or less than the treatment doses
used commercially. Illumination was performed using an
INTERCEPT illuminator (INT100, Cerus Corporation)
according to the instrument manual. The single 3.0 J/cm2
UVA treatment reflects the commercial INTERCEPT pro-
cess, whereas the 1.0 and 2.1 cm2 UVA treatments were
used to demonstrate inactivation kinetics. Following each illu-
mination (single 1.0 J/cm2, cumulative 2.1 J/cm2, and single
3.0 J/cm2), samples were withdrawn for CHIKV titer determi-
nation. All samples were frozen at −80°C until assayed.
To assess and quantify CHIKV viability, pre-illumination
and stock virus samples were 10-fold serially diluted in L-15
medium with 5 U/mL heparin (platelet samples) or EE
medium with 5 U/mL heparin (plasma samples). Heparin
was included in the diluents to prevent the formation of clots
when the anticoagulant in the blood product comes in contact
with the divalent cations in the culture medium. Clots are
disruptive to the cells and may cause a loss of assay sensitivity.
Post-illumination samples were diluted 1:5 (platelets) or 1:4
(plasma), 1:10, and 1:100 in the same diluents. For platelet
samples, 100 mL of each 1:10 and 1:100 dilution were added
to 8 wells of a 96-well plate and 100 mL of each 1:5 dilution
was added to 240 wells. One hundred mL of L-15 growth
medium with 5 U/mL heparin containing ~5 + 105 cells/mL
of Vero cells were added to each well of the plate and plates
were incubated at 37°C for 7 days before fixing and staining
with a fixative containing amido black. The plates were then
scored manually for infection by evaluating the cell mono-
layer for cytopathic effect. For plasma samples, 100 mL
of each dilution of the pre-illumination samples was added
to each of 6 wells of a 96-well plate containing Vero76 cells.
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The 1:4 dilution of each post-illumination plasma sample
was added to 216 wells (unit 1) or 72 wells (unit 2), and the
1:10 and 1:100 dilutions of all post-illumination plasma sam-
ples were added to 12 wells of a 96-well plate containing
Vero76 cells. The plates were incubated at 37°C in a humidi-
fied CO2 atmosphere and the cytopathic effect was evaluated
using a light microscope every 1–2 days starting on Day 3
and continuing through Day 7 or 8. Each well was scored
as positive or negative for cytopathic effect. Following scor-
ing, a titer was calculated for each sample using the method
of Reed and Muench59 based on the number of positive and
negative wells in each dilution. For samples in which no viable
CHIKV was detected in any of the wells inoculated (post-
UVA samples), the titer was calculated as less than what the
titer would be if one infectious virion were present in the total
volume of blood product assayed. A large number of wells
were inoculated with the 1:4 and 1:5 dilutions to maximize
the total amount of treated blood product evaluated and thus
to maximize the dynamic range of the assay and the level
of inactivation demonstrated. Mean titers and SD for four
replicates were expressed as TCID50/mL of sample.
RESULTS
To evaluate CHIKV inactivation in human apheresis plate-
let concentrates and plasma components by photochemical
treatment with amotosalen (150 mM) and UVA, CHIKV was
added to platelet concentrates to titers of ~6 log10TCID50/mL
(strain OPY1) and to plasma components to a titer of
~8 log10 TCID50/mL (strain S27). The two titers used represent
thehighest titers attainable for each strain tested.Vanlandingham
and others60 recently published themolecular characterization
of the OPY1 strain of CHIKV using a reverse transcription-
polymerase chain reaction assay and have correlated the infec-
tivity with the genomic equivalents per mL (gEq/mL). A 200:1
relationship was found indicating that the molecular titer
in platelets was ~8 log gEq/mL. If the ratio of gEq to infectious
titer is similar for the S27 strain as expected, molecular titers
of ~10 log gEq/mL were achieved in plasma since the starting
titer of CHIKV S27 was higher. The components were then
treated with amotosalen and 3.0, 2.1, or 1.0 J/cm2 UVA.
The CHIKV was completely inactivated to the limit of detec-
tion (< −0.7 Log10TCID50/mL) at all experimental conditions
in platelet components, resulting in inactivation of > 6.4 ± 0.6
log10TCID50 (Table 1). In plasma components, which were
inoculated with 100-fold more CHIKV because of the higher
stock virus titers achievable with strain S27, some residual
viable virus was detected in some replicates of all experimental
conditions (Table 2). However, inactivation to below the limit
of detection in the assay was observed in half of the replicates
following 3.0 J/cm2 UVA treatment and fewer than 1.3 log10
TCID50/mL was detected in the remaining replicates. Overall,
inactivation of ³ 7.6 ± 1.4 log TCID50 of CHIKV in plasma was
observed (Table 2). Given the 200:1 ratio between the TCID50
and gEq/mL, levels of inactivation of > 8.7 and > 9.9 log gEq
can be calculated for platelets and plasma, respectively, indi-
cating a level of protection comparable to the highest levels
of viremia observed in infected blood samples.61–63 Pre-
illumination titers of CHIKV in both blood components
were in the range of expected values based on the titer of
the stock virus, indicating that neither amotosalen alone nor
the blood products alone inactivated CHIKV, nor did the blood
Table 1
Chikungunya virus (strain OPY1) inactivation in platelet concentrates after photochemical treatment with 150 mM amotosalen and varying
UVA treatments
Replicate
Titer (Log10TCID50/mL) Log reduction*
Unit 1 Unit 2 Unit 1 Unit 2
Pre-UVA Post 3.0 J/cm2 Pre-UVA Post 1.0 J/cm2 Post 2.1 J/cm2 3.0 J/cm2 1.0 J/cm2 2.1 J/cm2
1 4.8 < −0.7 4.6 < −0.7 < −0.7 > 5.5 > 5.2 > 5.2
2 6.1 < −0.7 5.8 < −0.7 < −0.7 > 6.7 > 6.5 > 6.5
3 6.1 < −0.7 5.9 < −0.7 < −0.7 > 6.7 > 6.6 > 6.6
4 6.1 < −0.7 5.7 < −0.7 < −0.7 > 6.7 > 6.3 > 6.3
Mean ± SD† 5.7 ± 0.6 < −0.7 5.5 ± 0.6 < −0.7 < −0.7 > 6.4 ± 0.6 > 6.2 ± 0.6 > 6.2 ± 0.6
*Log reduction was calculated as log (pre-UVA titer  post-UVA titer) where titers are expressed as log10TCID50/mL. Log reduction was calculated from numbers that were not rounded.
Means and standard deviations (SD) were determined from numbers that were not rounded.
Table 2
Chikungunya virus (strain S27) inactivation in plasma after photochemical treatment with 150 mM amotosalen and varying UVA treatments
Replicate
Titer (Log10TCID50/mL)* Log reduction†
Unit 1 Unit 2 Unit 1 Unit 2
Pre-UVA Post 3.0 J/cm2 Pre-UVA Post 1.0 J/cm2 Post 2.1 J/cm2 3.0 J/cm2 1.0 J/cm2 2.1 J/cm2
1 8.8 < −0.7 8.8 1.0 to 1.3 1.0 to 1.3 > 9.5 7.5 to 7.8 7.5 to 7.8
2 6.9 < −0.7 7.3 1.1 to 1.3 < −0.3 > 7.6 6.0 to 6.3 > 7.6
3 8.4 1.0 to 1.3 8.5 1.1 to 1.3 −0.3 7.1 to 7.4 7.2 to 7.4 8.8
4 7.5 1.0 to 1.3 7.5 1.1 to 1.3 1.0 to 1.3 6.2 to 6.5 6.1 to 6.4 6.2 to 6.4
Mean ± SD‡ 7.8 ± 0.8 £ 0.3 ± 1.2 8.0 ± 0.8 1.1 to 1.3 £ 0.4 ± 0.7 ³ 7.6 ± 1.4 6.7 to 7.0 ³ 7.5 ± 1.1
*Best and worst case titers were determined for samples in which at least one but less than half of the wells were positive in the most concentrated dilution plated (1:4). The worst case assumed
that all the wells at the next lower dilution (undiluted) would have been positive if plated, and the best case assumed that 50% of the undiluted wells would have been positive if plated. Ranges
in log reduction data are the result of using both best and worst case titers in log reduction calculations. When no virus was detected in the lowest dilution plated, the titer was determined
to be < 1 in the total volume of blood product assayed.
†Log reduction was calculated as log (pre-UVA titer  post-UVA titer) where titers are expressed as Log10 TCID50/mL. Log reduction was calculated from numbers that were not rounded.
‡Means and standard deviations (SD) were determined from numbers that were not rounded. Only worst case determinations were used in the calculations of means and SDs that were ³ or £ the
stated value.
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products interfere with the sensitivity of detection of viable
CHIKV (Tables 1 and 2).
DISCUSSION
Over the course of the last several years CHIKV has become
one of the most important human pathogens in the alpha-
virus family. The CHIKV epidemic, which started in coastal
Kenya in 2004,4 rapidly spread into countries of South-East
Asia, Indian Ocean basin,5–13 and India14 affecting millions
of people. In addition, CHIKV was introduced into Europe
where it caused its first autochthonous outbreaks in 2007 and
2010.16–18 Vectored by domestic Ae. aegypti and peridomestic
Ae. albopictus mosquitoes widely distributed in the Old World
and the Americas, CHIKV could potentially expand its range
into the New World, where immunologically naive human
populations could facilitate rapid spread of the virus. The con-
sequences of such an event would have a considerable adverse
effect on transfusion medicine.1
In many regards, the potential impact of CHIKV on trans-
fusion medicine is similar to that of WNV, except that assays
for screening CHIKV in blood products, such as detection of
CHIKV RNA, have not been developed and implemented,
leaving deferral of donors based on travel history as the only
option for reducing the CHIKV transfusion risk in non-endemic
regions and no real options for risk reduction in endemic
regions.1 Although the majority of CHIKV infections are asso-
ciated with febrile illness (> 75%)34,35 and these donors can be
easily deferred, the viremic phase of CHIKV infections begins
1–2 days before the onset of symptoms, and about 6–20%
of infections remain asymptomatic.33 In addition, the extremely
high attack rate during CHIKV outbreaks suggests that a con-
siderable proportion of donated blood may be contaminated
with CHIKV in epidemic areas.
In this study, we showed that photochemical treatment
of human apheresis platelet and plasma components with
amotosalen and UVA effectively inactivates high concentra-
tions of CHIKV. In fact, the virus is sufficiently sensitive
to this photochemical treatment that complete inactivation
was achieved in platelet components with as little as one-third
the UVA dose used in the commercial treatment process.
In addition, the use of two different CHIKV strains, which
were isolated several decades apart shows that the virus retains
its sensitivity to inactivation, regardless of whatever mutations
may have accumulated over that time. The robust inactivation
achieved is particularly noteworthy in light of the fact that
CHIKVishighlyplatelet associated.64AsobservedbyChernesky
andothers64 andLarke andWheelock,65mixing of human plate-
lets with CHIKV leads to the sequestration of viral particles
inside platelets aggregates in a way that stabilizes the infectivity
of the virus. The sequestration is time dependent at 37°C.
Therefore, the fact that the virus used in these studies is not
produced in vivo does not appear to affect this property of the
virus. It is not known whether the virus is physically located
inside human platelets, or if the platelets aggregate and form
a protective coating for the viral aggregates.64,65 The results
of similar studies of the photochemical inactivation of CHIKV
using riboflavin and UV light (Mirasol Pathogen Reduction
[PR] System) in platelet components in platelet additive solu-
tion and in plasma components were recently published by
Vanlandingham and others.60 Using the same strain of CHIKV
used in the platelet studies presented here, 2.2 and 2.1 log reduc-
tions of CHIKV infectivity were observed in platelets and
plasma, respectively, treated with the Mirasol system. Interest-
ingly, higher inactivation was observed in cell culture media
indicating an inhibitory effect on the Mirasol PR system in the
presence of plasma and platelets. This may indicate protein
interference or it may be a result of the known sequestration
of CHIKV in platelets. This is in stark contrast to the results
obtained for this study, where high levels of inactivation were
achieved in the presence of platelets and of plasma, and may be
the result of mechanistic differences between the two systems.
Considering that human viremia does not reach levels
higher than 5–7 log10TCID50/mL
1,60,65–67 in ill individuals,
it appears that this technology will result in complete inacti-
vation of the presumably even lower levels of CHIKV
in platelet and plasma components collected from asymptom-
atic donors. Even though it is impossible to guarantee that an
infectious titer exceeding the capacity of the system will never
occur, INTERCEPT inactivation of more than 5–6 log titers
offers a significant risk reduction for transfusion-transmitted
infections with these pathogens. This is especially pertinent
in light of recent evidence that lower titer CHIKV viremia
may be associated with different clinical outcomes than high
titer viremia36; additionally, routine use of the pathogen inac-
tivation system may be a viable alternative to the deferral
of donors that have traveled in CHIKV endemic areas pro-
vided they meet the other screening criteria.
In northern Italy, all blood donations were halted during the
CHIKV outbreak and this resulted in an economic loss exceed-
ing 3 million euros1,31 caused by the expense of importing
blood to sustain a local supply. In this regard, photochemical
treatment of blood products with amotosalen and UVA could
significantly reduce the risk of CHIKV transmission, and thus,
represents an attractive means to prevent the disruption of a
local supply of blood products in the affected areas during
CHIKV outbreaks. This is particularly true of platelets because
of their limited shelf life of 5 days.68 This theory was put into
practice during the La Re´union outbreak when, in 2006,
French authorities implemented mandatory photochemical
treatment of platelet components with the INTERCEPT
Blood System to reduce the risk of CHIKV transmission on
La Re´union.32 Approximately 4,000 platelet units were admin-
istered over the course of 1 year, and no transfusion related
CHIKV transmissions were documented. Although pathogen
inactivation obviously adds cost to blood components, in the
context of the current testing paradigm and assuming that there
is no established nucleic acid test assay for a specific pathogen,
it has been found that pathogen inactivation is more cost effec-
tive than NAT in terms of quality-adjusted life years, a mea-
surement of clinical and cost effectiveness. Additionally, it has
been recognized that pathogen inactivation can also be seen as
an insurance policy against other chronic or acutely transmitted
pathogens.69 The INTERCEPT system is in fact already in use
in 17 countries and under evaluation in additional areas in
which CHIKV and other pathogens are endemic or epidemic.70
In summary, our study shows that photochemical treatment of
human apheresis platelet concentrates and plasma components
with amotosalen andUVAresults in efficient inactivation of high
levels of CHIKV that would reduce or eliminate transfusion-
transmitted infection. This suggests that photochemical treat-
ment of platelet or plasma components would be an effective
method for prevention of transfusion-transmitted CHIKV infec-
tion in the areas of CHIKVendemic/epidemic activity.
1166 TSETSARKIN AND OTHERS
Received September 28, 2012. Accepted for publication February 18,
2013.
Published online March 25, 2013.
Financial support: Funding for this study was provided by Cerus
Corporation.
Authors’ addresses: Konstantin A. Tsetsarkin, National Institutes of
Allergy and Infectious Diseases, Neurotropic Flaviviruses Section,
Bethesda, MD, E-mail: tsetsarkinka@niaid.nih.gov. Adam Sampson-
Johannes, Lynette Sawyer, and John Kinsey, Cerus Corporation,
Concord, CA, E-mails: Dna.3@sbcglobal.net, LSawyer@cerus.com,
and shotokando@aol.com. Stephen Higgs, Biosecurity Research
Institute, Kansas State University, Manhattan, KS, E-mail: shiggs@
k-state.edu. Dana L. Vanlandingham, Department of Diagnostic
Medicine and Pathobiology, College of Veterinary Medicine, Kansas
State University, Manhattan, KS, E-mail: dlvanlan@vet.k-state.edu.
REFERENCES
1. Petersen LR, Stramer SL, Powers AM, 2010. Chikungunya virus:
possible impact on transfusion medicine. Transfus Med Rev 24:
15–21.
2. Centers for Disease Control and Prevention, 2012. West Nile
Virus (WNV) Human Infections Reported to ArboNET by
State, United States, 2012 (as of September 18, 2012). Available
at: (http://www.cdc.gov/ncidod/dvbid/westnile/surv&control
CaseCount12_detailed.htm. Accessed September 20, 2012.
3. Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi
LS, Bedno S, Burke H, Dumilla AM, Konde J, Njenga MK,
Sang R, Breiman RF, 2008. Seroprevalence of chikungunya
virus (CHIKV) infection on Lamu Island, Kenya, October 2004.
Am J Trop Med Hyg 78: 333–337.
4. Kariuki Njenga M, Nderitu L, Ledermann JP, Ndirangu A, Logue
CH, Kelly CH, Sang R, Sergon K, Breiman R, Powers AM,
2008. Tracking epidemic chikungunya virus into the Indian
Ocean from East Africa. J Gen Virol 89: 2754–2760.
5. Sergon K, Yahaya AA, Brown J, Bedja SA, Mlindasse M, Agata N,
Allaranger Y, Ball MD, Powers AM, Ofula V, Onyango C,
Konongoi LS, Sang R, Njenga MK, Breiman RF, 2007. Seroprev-
alence of chikungunya virus infection on Grande Comore Island,
Union of the Comoros, 2005.Am J TropMedHyg 76: 1189–1193.
6. Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L,
Vaney MC, Lavenir R, Pardigon N, Reynes JM, Pettinelli F,
Biscornet L, Diancourt L, Michel S, Duquerroy S, Guigon G,
Frenkiel MP, Brehin AC, Cubito N, Despres P, Kunst F,
Rey FA, Zeller H, Brisse S, 2006. Genome microevolution
of chikungunya viruses causing the Indian Ocean outbreak.
PLoS Med 3: e263.
7. International Society for InfectiousDiseases, 2010.CHIKUNGUNYA,
(04): MADAGASCAR (FIANARANTSOA). Archive number
2010026.0639. Available at: http://www.promedmail.org. Accessed
September 25, 2012.
8. Kularatne SA, Gihan MC, Weerasinghe SC, Gunasena S, 2009.
Concurrent outbreaks of chikungunya and dengue fever in
Kandy, Sri Lanka, 2006–07: a comparative analysis of clinical
and laboratory features. Postgrad Med J 85: 342–346.
9. Yoosuf AA, Shiham I, Mohamed AJ, Ali G, Luna JM, Pandav R,
Gongal GN, Nisaluk A, Jarman RG, Gibbons RV, 2009. First
report of chikungunya from the Maldives. Trans R Soc Trop
Med Hyg 103: 192–196.
10. Sam IC, Chan YF, Chan SY, Loong SK, Chin HK, Hooi PS,
Ganeswrie R, Abubakar S, 2009. Chikungunya virus of Asian
and Central/East African genotypes in Malaysia. J Clin Virol
46: 180–183.
11. AbuBakar S, Sam IC, Wong PF, MatRahim N, Hooi PS, Roslan
N, 2007. Reemergence of endemic chikungunya, Malaysia.
Emerg Infect Dis 13: 147–149.
12. Ng LC, Tan LK, Tan CH, Tan SS, Hapuarachchi HC, Pok KY,
Lai YL, Lam-Phua SG, Bucht G, Lin RT, Leo YS, Tan BH,
Han HK, Ooi PL, James L, Khoo SP, 2009. Entomologic and
virologic investigation of chikungunya, Singapore.Emerg Infect
Dis 15: 1243–1249.
13. Rianthavorn P, Prianantathavorn K, Wuttirattanakowit N,
Theamboonlers A, Poovorawan Y, 2010. An outbreak of
chikungunya in southern Thailand from 2008 to 2009 caused
by African strains with A226V mutation. Int J Infect Dis 14
(Suppl 3): e161–e165.
14. Yergolkar PN, Tandale BV, Arankalle VA, Sathe PS, Sudeep
AB, Gandhe SS, Gokhle MD, Jacob GP, Hundekar SL, Mishra
AC, 2006. Chikungunya outbreaks caused by African geno-
type, India. Emerg Infect Dis 12: 1580–1583.
15. InternationalSociety for InfectiousDiseases, 2010.CHIKUNGUNYA,
(30): CHINA (GUANGDONG), REUNION. Archive number
20101008.3661. Available at: http://www.promedmail.org. Accessed
September 25, 2012.
16. Angelini R, Finarelli AC, Angelini P, Po C, Petropulacos K, Silvi
G, Macini P, Fortuna C, Venturi G, Magurano F, Fiorentini C,
Marchi A, Benedetti E, Bucci P, Boros S, Romi R, Majori G,
Ciufolini MG, Nicoletti L, Rezza G, Cassone A, 2007.
Chikungunya in north-eastern Italy: a summing up of the out-
break. Euro Surveill 12: E071122.2.
17. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning
M, Cordioli P, Fortuna C, Boros S, Magurano F, Silvi G,
Angelini P, Dottori M, Ciufolini MG, Majori GC, Cassone A,
2007. Infection with chikungunya virus in Italy: an outbreak
in a temperate region. Lancet 370: 1840–1846.
18. Grandadam M, Caro V, Plumet S, Thiberge JM, Souares Y,
Failloux AB, Tolou HJ, Budelot M, Cosserat D, Leparc-
Goffart I, Despres P, 2011. Chikungunya virus, southeastern
France. Emerg Infect Dis 17: 910–913.
19. Schwartz O, Albert ML, 2010. Biology and pathogenesis of
chikungunya virus. Nat Rev Microbiol 8: 491–500.
20. Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani
KV, 2008. Increased mortality rate associated with chikungunya
epidemic, Ahmedabad, India. Emerg Infect Dis 14: 412–415.
21. Casolari S, Briganti E, Zanotti M, Zauli T, Nicoletti L, Magurano
F, Fortuna C, Fiorentini C, Grazia Ciufolini M, Rezza G,
2008. A fatal case of encephalitis associated with chikungunya
virus infection. Scand J Infect Dis 40: 995–996.
22. Ganesan K, Diwan A, Shankar SK, Desai SB, Sainani GS, Katrak
SM, 2008. Chikungunya encephalomyeloradiculitis: report of
2 cases with neuroimaging and 1 case with autopsy findings.
AJNR Am J Neuroradiol 29: 1636–1637.
23. Josseran L, Paquet C, Zehgnoun A, Caillere N, Le Tertre A,
Solet JL, Ledrans M, 2006. Chikungunya disease outbreak,
Reunion Island. Emerg Infect Dis 12: 1994–1995.
24. Ramchurn SK, Goorah SS, Makhan M, Moheeput K, 2008. Excess
mortality as an epidemic intelligence tool in chikungunya
mapping. Euro Surveill 13: 8039.
25. Tandale BV, Sathe PS, Arankalle VA, Wadia RS, Kulkarni R,
Shah SV, Shah SK, Sheth JK, Sudeep AB, Tripathy AS,
Mishra AC, 2009. Systemic involvements and fatalities during
chikungunya epidemic in India, 2006. J Clin Virol 46: 145–149.
26. Powers AM, Logue CH, 2007. Changing patterns of chikungunya
virus: re-emergence of a zoonotic arbovirus. J Gen Virol 88:
2363–2377.
27. Jupp PG, McIntosh BM, 1988. Chikungunya virus disease.
Monath TP, ed. The Arboviruses: Epidemiology and Ecology.
Boca Raton, FL: CRC Press, 137–157.
28. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S, 2007.
A single mutation in chikungunya virus affects vector specific-
ity and epidemic potential. PLoS Pathog 3: e201.
29. Tsetsarkin KA, Chen R, Leal G, Forrester N, Higgs S, Huang J,
Weaver SC, 2011. Chikungunya virus emergence is constrained
in Asia by lineage-specific adaptive landscapes. Proc Natl
Acad Sci USA 108: 7872–7877.
30. Benedict MQ, Levine RS, Hawley WA, Lounibos LP, 2007.
Spread of the tiger: global risk of invasion by the mosquito
Aedes albopictus. Vector Borne Zoonotic Dis 7: 76–85.
31. Liumbruno GM, Calteri D, Petropulacos K, Mattivi A, Po C,
Macini P, Tomasini I, Zucchelli P, Silvestri AR, Sambri V,
Pupella S, Catalano L, Piccinini V, Calizzani G, Grazzini G,
2008. The chikungunya epidemic in Italy and its repercussion
on the blood system. Blood Transfus 6: 199–210.
32. Rasongles P, Angelini-Tibert MF, Simon P, Currie C, Isola H,
Kientz D, Slaedts M, Jacquet M, Sundin D, Lin L, Corash L,
Cazenave JP, 2009. Transfusion of platelet components pre-
pared with photochemical pathogen inactivation treatment
during a chikungunya virus epidemic in Ile de La Reunion.
Transfusion 49: 1083–1091.
PHOTOCHEMICAL INACTIVATION OF CHIKUNGUNYA VIRUS 1167
33. Brouard C, Bernillon P, Quatresous I, Pillonel J, Assal A, De
Valk H, Desenclos JC, 2008. Estimated risk of Chikungunya
viremic blood donation during an epidemic on Reunion Island
in the Indian Ocean, 2005 to 2007. Transfusion 48: 1333–1341.
34. Sissoko D, Moendandze A, Malvy D, Giry C, Ezzedine K, Solet JL,
Pierre V, 2008. Seroprevalence and risk factors of chikungunya
virus infection inMayotte, IndianOcean, 2005–2006: a population-
based survey. PLoS ONE 3: e3066.
35. Queyriaux B, Simon F, GrandadamM,Michel R, Tolou H, Boutin
JP, 2008. Clinical burden of chikungunya virus infection. Lancet
Infect Dis 8: 2–3.
36. Appassakij H, Khuntikij P, Kemapunmanus M, Wutthanarungsan
R, Silpapojakul K, 2012. Viremic profiles in asymptomatic and
symptomatic chikungunya fever: a blood transfusion threat?
Transfusion 26: [Epub ahead of print], doi:10.1111/j.1537-2995.
2012.03960.x.
37. Gerardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard
P, Michault A, de Lamballerie X, Flahault A, Favier F, 2008.
Estimating chikungunya prevalence in La Reunion Island
outbreak by serosurveys: two methods for two critical times of
the epidemic. BMC Infect Dis 8: 99.
38. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK,
Metzel P, Corash L, 2005. Inactivation of viruses in platelet
concentrates by photochemical treatment with amotosalen
and long-wavelength ultraviolet light. Transfusion 45: 580–590.
39. Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K,
2003. Trypanosoma cruzi inactivation in human platelet concen-
trates and plasma by a psoralen (amotosalen HCl) and long-
wavelength UV. Antimicrob Agents Chemother 47: 475–479.
40. SinghY,SawyerLS,PinkoskiLS,DupuisKW,HsuJC,LinL,Corash
L, 2006. Photochemical treatment of plasma with amotosalen and
long-wavelength ultraviolet light inactivates pathogens while
retaining coagulation function.Transfus 46: 1168–1177.
41. Lin L, Dikeman R, Molini B, Lukehart S, Lane R, Dupuis K,
Metzel P, Corash L, 2004. Photochemical treatment of platelet
concentrates with amotosalen and long-wavelength ultraviolet
light inactivates a broad spectrum of pathogenic bacteria.
Transfusion 44: 1496–1504.
42. Grellier P, Benach J, Labaied M, Cahrneau S, Gil H, Monsalve G,
Alfonso R, Sawyer L, Lin L, Steiert M, Dupuis K, 2008. Photo-
chemical inactivation with amotosalen and long-wavelength
ultraviolet light of Plasmodium and Babesia in platelet and
plasma components. Transfusion 48: 1676–1684.
43. Sawyer L, Hanson D, Castro G, Luckett W, Dubensky TW,
Stassinopoulos A, 2007. Inactivation of parvovirus B19 in human
platelet concentrates by treatment with amotosalen and ultra-
violet A illumination. Transfusion 47: 1062–1070.
44. Grass JA, Hei DJ, Metchette K, Cimino GD, Weisenhahn GP,
Corash L, Lin L, 1998. Inactivation of leukocytes in platelet
concentrates by photochemical treatment with psoralen plus
UVA. Blood 91: 2180.
45. Eastman RT, Barrett LK, Dupuis K, Buckner FS, Van Voorhis
WC, 2005. Leishmania inactivation in human pheresis platelets
by a psoralen (amotosalen HCl) and long-wavelength ultra-
violet irradiation. Transfusion 45: 1459–1463.
46. Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino
GD, Corten L, Damonte PB, Dikeman R, Dupuis K, Fang
YM, Hanson CV, Hearst JE, Lin CY, Londe HF, Metchette
K, Nerio AT, Pu JT, Reames AA, Rheinschmidt M, Tessman
J, Isaacs ST, Wollowitz S, Corash L, 1997. Photochemical inac-
tivation of viruses and bacteria in platelet concentrates by use
of a novel psoralen and long-wavelength ultraviolet light.
Transfusion 37: 423–435.
47. Wollowitz S, 2001. Fundamentals of the psoralen-based helinx
technology for inactivation of infectious pathogens and leuko-
cytes in platelets and plasma. Semin Hematol 38 (Suppl 11): 4–11.
48. Irsch J, Pinkoski L, Corash L, Lin L, 2010. INTERCEPT plasma:
comparability with conventional fresh-frozen plasma based on
coagulation function – an in vitro analysis. Vox Sang 98: 47–55.
49. Lin L, Alfonso R, Behrman B, Corten L, Damonte PB, Dikeman
R, Dupuis K, Hei D, Lin CY, Londe HF, Metchette K, Phan T,
Reames AA, Rheinschmidt M, Savoor A, Tessman J, Corash
L, 1998. Photochemical treatment of platelet concentrates with
a novel psoralen and UVA to enhance the safety of platelet
transfusions. Infusther Tranfsusmed 25: 39–48.
50. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A,
Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss
RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S,
Howard FT, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos
A, Lin L, Buchholz DH, Conlan MG, 2004. Therapeutic effi-
cacy and safety of platelets treated with a photochemical pro-
cess for pathogen inactivation: the SPRINT Trial. Blood 104:
1534–1541.
51. de Alarcon P, Benjamin R, Dugdale M, Kessler C, Shopnick R,
Smith P, Abshire T, Hambleton J, Matthew P, Ortiz I, Cohen
A, Konkle BA, Streiff M, Lee M, Wages D, Corash L, 2005.
Fresh frozen plasma prepared with amotosalen HCl (S-59)
photochemical pathogen inactivation: transfusion of patients
with congenital coagulation factor deficiencies. Transfusion
45: 1362–1372.
52. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D,
Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M,
de Greef G, Laforet M, Lioure B, Davis K, Marblie S,
Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz
D, Corash L, 2003. Transfusion of pooled buffy coat platelet
components prepared with photochemical pathogen inactiva-
tion treatment: the euroSPRITE trial. Blood 101: 2426–2433.
53. Lin L, Conlan MG, Tessman J, Cimino G, Porter S, 2005.
Amotosalen interactions with platelet and plasma components:
absence of neoantigen formation after photochemical treat-
ment. Transfusion 45: 1610–1620.
54. ANSM, 2013. French Agency for the Safety of Health Products.
France Annual Haemovigilance report 2009. Available at:
http://www.ansm.sante.fr/Mediatheque/Publications/Informa-
tion-in-English. Accessed September 20, 2012.
55. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M,
Raidot JP, Kandel G, Wiesel ML, Corash L, 2011. Use of
additive solutions and pathogen inactivation treatment of plate-
let components in a regional blood center: impact on patient
outcomes and component utilization during a 3-year period.
Transfusion 51: 622–629.
56. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat
M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I,
Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D,
Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M,
Sundin D, Lin L, Corash L, 2008. An active haemovigilance
programme characterizing the safety profile of 7437 platelet
transfusions prepared with amotosalen photochemical treat-
ment. Vox Sang 94: 315–323.
57. Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N,
Van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L, 2009.
Universal adoption of pathogen inactivation of platelet
components: impact on platelet and red blood cell component
use. Transfusion 49: 1412–1422.
58. Devine DV, Sher GD, Reesink HW, Panzer S, Hetzel PA, Wong
JK, Horvath M, Leitner GC, Schennach H, Nussbaumer W,
Genoe K, Cioffi JM, Givisiez FN, Rogerson M, Howe D,
Delage G, Sarappa C, Charbonneau, Fu Y, Sarlija D, Vuk T,
Strauss Patko M, Balija M, Jukic I, Ali A, Auvinen MK,
Jaakonsalo E, Cazenave JP, Waller C, Kientz D, David B,
Walther-Wenke G, Heiden M, Lin CK, Tsoi WC, Lee CK,
Barotine-Toth K, Sawant RB, Murphy W, Quirke B, Bowler
P, Shinar E, Yahalom V, Aprili G, Piccoli P, Gandini G,
Tadokaro K, Nadarajan VS, de Kort W, Jansen N, Flanagan
P, Forsberg PO, Hervig T, Letowska M, Lachert E, Dudziak
K, Antoniewicz-Papis J, de Olim G, Nascimento F, Hindawi
S, Teo D, Reddy R, Scholtz J, Swanevelder R, Rovira LP,
Sauleda S, Carasa MA, Vaquero MP, Ania MA, Gulliksson H,
Holdsworth S, Cotton S, Howell C, Baldwin C, Cusick RM,
Geele GA, Paden C, McEvoy P, Gottschall JL, McLaughlin
LS, Benjamin RJ, Eder A, Draper NL, AuBuchon JP, Leon
de Gonzalez G, 2010. Inventory management. Vox Sang 98:
e295–e363.
59. Reed LJ, Muench H, 1938. A simple method for estimating fifty
per cent endpoints. Am J Hyg 27: 493–497.
60. Vanlandingham DL, Keil SD, McElroy Horne K, Pyles R,
Goodrich RP, Higgs S, 2012. Photochemical inactivation
of chikungunya virus in plasma and platelets using the
Mirasol pathogen reduction technology system. Transfusion 53:
284–290.
1168 TSETSARKIN AND OTHERS
61. Leo YS, Chow ALP, Tan LK, Lye DC, Lin L, Ng LC, 2009.
Chikungunya outbreak, Singapore 2008. Emerg Infect Dis 15:
836–837.
62. Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-
Benhassine F, Rudnicka D, Sol-Foulon N, Le Roux K, Prevost
MC, Fsihi H, Frenkiel MP, Blanchet F, Afonso PV, Ceccaldi
PE, Ozden S, Gessain A, Schuffenecker I, Verhasselt B,
Zamborlini A, Saı¨b A, Rey FA, Arenzana-Seisdedos F,
Despre`s P, Michault A, Schwartz O, 2007. Characterization of
reemerging chikungunya virus. PLoS Pathog 3: e89.
63. McIntosh BM, Paterson HE, Donaldson JM, de Sousa J, 1963.
Chikungunya virus: viral susceptibility and transmission studies
with some vertebrates. S Afr J Med Sci 28: 45.
64. Chemsky MA, Larke RP, 1977. Contrasting effects of rabbit
and human platelets on chikungunya virus infectivity. Can J
Microbiol 23: 1237–1244.
65. Larke RP, Wheelock EF, 1970. Stabilization of chikungunya virus
infectivity by human blood platelets. J Infect Dis 122: 523–531.
66. Parola P, de Lamballerie X, Jourdan J, Rovery C, Vaillant V,
Minodier P, Brouqui P, Flahault A, Raoult D, Charrel RN,
2006. Novel chikungunya virus variant in travelers returning
from Indian Ocean islands. Emerg Infect Dis 12: 1493–1499.
67. Carletti F, Bordi L, Chiappini R, Ippolito G, Sciarrone MR,
Capobianchi MR, Di Caro A, Castilletti C, 2007. Rapid detec-
tion and quantification of chikungunya virus by a one-step
reverse transcription polymerase chain reaction real-time
assay. Am J Trop Med Hyg 77: 521–524.
68. Tomson B, Brand A, 2010. In vivo tracking of transfused platelets
for recovery and survival studies: an appraisal of labeling
methods. Transfus Apheresis Sci 42: 53–61.
69. Custer B, Agapova M, Martinez RH, 2010. The cost-effectiveness
of pathogen reduction technology as assessed using a multiple
risk reduction model. Transfusion 50: 2461–2473.
70. INTERCEPT In Use, 2012. Intercept Blood System. Available at:
www.interceptbloodsystem.com/intercept-in-use/overview.html.
Accessed December 15, 2012.
PHOTOCHEMICAL INACTIVATION OF CHIKUNGUNYA VIRUS 1169
